Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience

Area of Science:

• Medical Oncology
• Clinical Trials
• Surgical Oncology

Background:

• The Scandinavian Sarcoma Group (SSG) initiated chemotherapy research for soft tissue sarcoma (STS) in 1981.
• Initial studies evaluated single-agent doxorubicin as adjuvant therapy, yielding no significant improvements in survival.
• Subsequent research explored combination chemotherapy regimens for localized resectable STS.

Purpose of the Study:

• To evaluate the efficacy of adjuvant chemotherapy in patients with high-grade soft tissue sarcoma.
• To assess the impact of single-agent and combination chemotherapy on survival outcomes in STS.
• To investigate the potential benefits of adjuvant ifosfamide and doxorubicin in selected STS patients.

Main Methods:

• Prospective randomized trials and phase II studies were conducted by the SSG.
• Studies involved adjuvant single-agent doxorubicin, and combination chemotherapy (ifosfamide, etoposide) with growth factor support.
• Current research (SSG XIII) focuses on adjuvant ifosfamide and doxorubicin post-surgery in high-risk STS patients.

Main Results:

• The first study (SSG I) using adjuvant doxorubicin showed no improvement in overall or disease-free survival.
• A phase II study (SSG X) with combination chemotherapy demonstrated a high response rate (42%) in untreated patients.
• Meta-analyses suggest improved disease-free survival and a trend towards improved overall survival with adjuvant chemotherapy.

Conclusions:

• Adjuvant chemotherapy for localized resectable STS has shown mixed results, with early trials offering limited benefits.
• Combination chemotherapy regimens and specific patient selection may improve outcomes in STS.
• Ongoing trials continue to explore the role of adjuvant chemotherapy in improving survival for high-grade STS.